News
Herald Therapeutics Receives Sixth Global Patent
The United States Patent and Trademark Office (USPTO) grant extends the ThyrOxy intellectual property estate to six issued global patents. The new claims protect a lung-delivered T3 composition paired with an inhibitor of deiodinase-3 (D3), the enzyme that inactivates thyroid hormone in the injured lung, and extend method claims to congestive heart failure.
Herald Therapeutics Appoints Paul P. Friel to Board of Directors
Veteran pharmaceutical executive brings 30+ years of commercialization, international markets, business development, and M&A experience to support ThyrOxy platform development.
Herald Therapeutics Presents at the ATS Respiratory Innovation Summit
Dr. David Ingbar presents Herald’s evolution into a platform company, advancing multiple indications across two delivery forms, at the Breakthroughs in Critical Care Showcase.
Wade A. Smith Appointed Chief Executive Officer
Veteran biopharmaceutical executive brings deep capital-raising, M&A, and product launch experience to lead ThyrOxy platform development.
Herald Therapeutics Receives Fifth Global Patent
The USPTO grant extends ThyrOxy intellectual property estate to five issued global patents and protects a novel clinical dosing methodology developed by Herald’s scientific co-founders. The new claims protect direct-to-lung T3 administration with serum-guided dose titration in ARDS.
Co-Founders Awarded $1 Million Grant to Develop Congestive Heart Failure Drug Candidate
David Ingbar, MD, and Robert Schumacher, PhD, receive a $1 million Transformational Research Award from the Dr. Ralph and Marian Falk Medical Research Trust.
Herald Therapeutics Awarded Second Place in Division at 2025 MN Cup
Herald Therapeutics awarded second place in the Life Science/HealthIT division at the 2025 MN Cup competition, out of 144 competitors.
Co-Founders Awarded Grant to Develop Novel Therapeutic Candidates for Premature Infants
Robert J. Schumacher, PhD, and David H. Ingbar, MD, have received a $106,300 grant from the Minnesota Partnership for Biotechnology and Medical Genomics, through the Translational Product Development Fund.
Co-Founders Receive Award to Develop Aerosolized ThyrOxy
David Ingbar, MD, and Robert Schumacher, PhD, receive a two-year, $350,000 Catalyst Research Award from the Dr. Ralph and Marion Falk Medical Research Trust.